FLASH NEWS LIVE

Novartis to buy Avidity Biosciences for $12 billion

Novartis to buy Avidity Biosciences for $12 billion

The move strengthens Novartis’s foothold in rare muscle disorder treatments as it faces a looming patent cliff for key drugs like Entresto, Xolair and Cosentyx

Read Full Article →

📱 Tip: Tap the 🔗 Share icon in Safari and choose Add to Home Screen to install World Trade Factory.
Instagram Meta X LinkedIn Whatsapp